Citadel Advisors LLC Purchases 56,400 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL)

Citadel Advisors LLC lifted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 58.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,675 shares of the company's stock after purchasing an additional 56,400 shares during the period. Citadel Advisors LLC owned 2.00% of Precision BioSciences worth $586,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Lynx1 Capital Management LP purchased a new position in Precision BioSciences in the 4th quarter valued at approximately $2,919,000. Moloney Securities Asset Management LLC boosted its stake in Precision BioSciences by 177.0% in the 4th quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company's stock worth $335,000 after purchasing an additional 56,100 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Precision BioSciences in the fourth quarter worth about $211,000. Jane Street Group LLC purchased a new position in Precision BioSciences during the fourth quarter worth about $146,000. Finally, Renaissance Technologies LLC raised its position in shares of Precision BioSciences by 36.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,798 shares of the company's stock valued at $418,000 after buying an additional 29,200 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company's stock.

Precision BioSciences Stock Down 2.9%

Shares of NASDAQ DTIL traded down $0.15 during trading on Wednesday, reaching $5.00. The company had a trading volume of 44,853 shares, compared to its average volume of 183,771. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $13.27. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The business's 50-day moving average is $4.95 and its 200 day moving average is $5.18. The stock has a market cap of $55.44 million, a PE ratio of 83.35 and a beta of 1.55.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $5.00 million. As a group, equities analysts forecast that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, May 21st.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.